An innovative medical technology company developing and delivering unique medical devices to improve surgical outcomes and patient recovery
Using state-of-the-art technology platforms to produce versatile bioresorbable and biocompatible synthetic polymers
Developing medical devices for use in targeted clinical applications to drive natural tissue repair and regeneration
Oakland, N.J., Groningen, The Netherlands, October 5, 2022 – Collagen Matrix, Inc. (“Collagen Matrix”), a global leader in regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, today announced the acquisition of Polyganics, B.V (“Polyganics”). Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the Company.
European Association of Neurosurgical Societies (EANS) – 19th European Congress of Neurosurgery
September 24- September 28, 2019
Dublin, Ireland
Visit booth #56
Oral presentations – Friday September 27, 2019 – 10:00-10:40- Poster booth 1 (E poster area):
